Is Johnson & Johnson's $1 Billion Cell Therapy Investment a Game Changer

Related Articles

Why is Johnson & Johnson Selling its Orthopedics Unit

6 months ago

Johnson & Johnson's "New Era" of Growth: Why the Market Underestimates Its Innovative Pipeline

2 months ago

What's Driving Johnson Controls' Recent Momentum Ahead of Q2 Earnings

4 months ago

What Makes Tethis' SmartBioSurface® a Game-Changer in Cell Analysis

2 months ago

Category

You may also like

Stock News•4 days ago

Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform

Celularity and MuseCell Innovations announced a U.S. manufacturing collaboration to produce Dezawa MuseCells at Celularity's Florham Park, N.J. facility, expanding domestic production capacity for the...

CELU

Share

Stock News•1 months ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Johnson & Johnson agreed to pay $785 million upfront for an exclusive option to acquire Sail Biomedicines for $2.58 billion, expanding its pipeline in programmable medicines.

JNJ

Share

Stock News•2 months ago

FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

FDA expanded Casgevy approval to children aged 2+ with sickle cell disease or β thalassemia, potentially broadening the addressable patient population for Vertex and CRISPR Therapeutics.

Share